SCHEMBL6077436

SCHEMBL6077436

NC(=O)C(Cc1ccc(Cl)cc1)Cc1ccc(Cl)cc1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.54
SLC6A2 P23975 1/20 0.50
SLC6A3 Q01959 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
PPARG P37231 2/20 0.47
PPARA Q07869 1/20 0.47
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
EPHX2 P34913 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NPC1 O15118 1/20 0.44
EPHX1 P07099 1/20 0.43
IDO1 P14902 1/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8122168 0.82 SLC6A4 (0.57) SLC6A4SLC6A2SLC6A3CYP2C9CYP2C19
SCHEMBL5096121 0.82 SLC6A4 (0.57) SLC6A4SLC6A2SLC6A3CYP2C9CYP2C19
SCHEMBL6317469 0.82 SLC6A4 (0.57) SLC6A4SLC6A2SLC6A3CYP2C9CYP2C19
SCHEMBL1901447 0.82 SLC6A4 (0.52) SLC6A4SLC6A2SLC6A3CYP2C9CYP2C19
SCHEMBL4663230 0.81 CYP1A2 (0.65) SLC6A4PPARGPPARAKMT2AEPHX2
Hydrochloric Acid SCHEMBL8335060 0.80 SLC6A4 (0.55) SLC6A4SLC6A2SLC6A3CYP2C9CYP2C19
SCHEMBL20824989 0.80 SLC6A4 (0.50) SLC6A4SLC6A2SLC6A3CYP2C9CYP2C19
SCHEMBL7772237 0.79 EPHX1 (0.46) EPHX1IDO1CYP1A2
SCHEMBL11298234 0.79 SLC6A4 (0.48) SLC6A4SLC6A2SLC6A3CYP2C9CYP2C19
SCHEMBL4619329 0.79 PPARG (0.55) SLC6A4CYP2C9CYP2C19PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890942-B2 Acyl sulfonamides as inhibitors of HIV integrase BRISTOL-MYERS SQUIBB COMPANY (US) 2005-05-10 US claimed
US-20050004232-A1 Acyl sulfonamides as inhibitors of HIV integrase BRISTOL-MYERS SQUIBB COMPANY 2005-01-06 US claimed
WO-2004103278-A2 ACYL SULFONAMIDES AS INHIBITORS OF HIV INTEGRASE BRISTOL-MYERS SQUIBB COMPANY (US) 2004-12-02 WO claimed
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 US disclosed
US-6890942-B2 Acyl sulfonamides as inhibitors of HIV integrase BRISTOL-MYERS SQUIBB COMPANY (US) 2005-05-10 US disclosed
US-20050004232-A1 Acyl sulfonamides as inhibitors of HIV integrase BRISTOL-MYERS SQUIBB COMPANY 2005-01-06 US disclosed
WO-2004103278-A2 ACYL SULFONAMIDES AS INHIBITORS OF HIV INTEGRASE BRISTOL-MYERS SQUIBB COMPANY (US) 2004-12-02 WO disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 US disclosed
WO-2004004657-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004232-A1 Acyl sulfonamides as inhibitors of HIV integrase ACSS2, ARSA, ASS1 SLC6A4 3732/4885SLC6A2 3628/4885SLC6A3 3002/4885
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF SLC6A4 4141/4885SLC6A2 3531/4885SLC6A3 3643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.